Medifast (MED) Projected to Post Earnings on Tuesday

Medifast (NYSE:MED) is expected to be issuing its Q4 2025 results after the market closes on Tuesday, February 17th. Analysts expect the company to announce earnings of ($0.80) per share and revenue of $71.40 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 4:30 PM ET.

Medifast Price Performance

Shares of MED opened at $10.78 on Friday. The company has a 50 day simple moving average of $11.37 and a two-hundred day simple moving average of $12.37. Medifast has a 1 year low of $10.10 and a 1 year high of $16.66. The firm has a market cap of $118.42 million, a P/E ratio of 1,077.50 and a beta of 0.53.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Wall Street Zen upgraded shares of Medifast from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Weiss Ratings reiterated a “sell (d)” rating on shares of Medifast in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $16.50.

Hedge Funds Weigh In On Medifast

Several large investors have recently bought and sold shares of the business. Caption Management LLC bought a new position in Medifast in the 2nd quarter worth approximately $244,000. Prudential Financial Inc. acquired a new position in Medifast during the 2nd quarter worth $200,000. JPMorgan Chase & Co. boosted its position in Medifast by 2.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 53,341 shares of the specialty retailer’s stock worth $749,000 after acquiring an additional 1,316 shares during the period. AQR Capital Management LLC grew its stake in shares of Medifast by 14.5% in the first quarter. AQR Capital Management LLC now owns 199,750 shares of the specialty retailer’s stock worth $2,693,000 after purchasing an additional 25,366 shares in the last quarter. Finally, Amundi increased its holdings in shares of Medifast by 43.5% during the first quarter. Amundi now owns 30,439 shares of the specialty retailer’s stock valued at $398,000 after purchasing an additional 9,224 shares during the period. Hedge funds and other institutional investors own 95.51% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.